4.2.3. Chronic pain and LTOT
One planned eight-week open-label non-randomized study with a six-month
follow of those with chronic pain on LTOT is ongoing. This study will
investigate the effect of psilocybin and psilocybin-assisted therapy in
one of two dosing sessions (25mg and 37.5mg) with the first occurring
during the period of opioid tapering.
[NCT05585229].83